Scientists map immune cells in rare cancer to boost treatment

NCT ID NCT07561190

Recruiting now Knowledge-focused Sponsor: Azienda USL Reggio Emilia - IRCCS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the immune system inside malignant pleural mesothelioma, a rare and hard-to-treat cancer. Researchers will analyze tumor samples from 300 adults to understand why immunotherapy helps only some patients. The goal is to find clues that could make these treatments more effective in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL MESOTHELIOMA (MPM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pleural mesothelioma Mesothelioma, Malignant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT PLEURAL MESOTHELIOMA (MPM)

Contacts and locations

Locations

Azienda Ospedaliera Universitaria Luigi Vanvitelli, Napoli
RECRUITING

Naples, Italy
Azienda Ospedaliera Universitaria Policlinico Rodolico San Marco di Catania
RECRUITING

Catania, Italy
Azienda USL IRCCS di Reggio Emilia
RECRUITING

Reggio Emilia, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RECRUITING

Roma, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.